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Abstract
Background: CXCR7 and CXCR4 are receptors for the chemokine CXCL12, which is involved in essential functions of the
immune and nervous systems. Although CXCR7 transcripts are widely expressed throughout the central nervous system,
little is known about its protein distribution and function in the adult brain. To evaluate its potential involvement in
CXCL12/CXCR4 signaling in differentiated neurons, we studied CXCR7 protein expression in human brain and cultured
neurons.
Methodology/Principal Findings: Immunohistochemistry and RT-PCR analyses of cortex and hippocampus from control
and HIV-positive subjects provided the first evidence of CXCR7 protein expression in human adult neurons, under normal
and pathological conditions. Furthermore, confocal microscopy and binding assays in cultured neurons show that CXCR7
protein is mainly located into cytoplasm, while little to no protein expression is found on neuronal plasma membrane.
Interestingly, specific CXCR7 ligands that inhibit CXCL12 binding to CXCR7 do not alter CXCR4-activated survival signaling
(pERK/pAkt) in rat cortical neurons. Neuronal CXCR7 co-localizes to some extent with the endoplasmic reticulum marker
ERp29, but not with early/late endosome markers. Additionally, large areas of overlap are detected in the intracellular
pattern of CXCR7 and CXCR4 expression.
Conclusions/Significance: Overall, these results implicate CXCR4 as the main CXCL12 signaling receptor on the surface of
differentiated neurons and suggest that CXCR7 may interact with CXCR4 at the intracellular level, possibly affecting CXCR4
trafficking and/or coupling to other proteins.
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Introduction
CXCR7, formerly known as RDC1, is a recently identified bin-
ding partner for the chemokine CXCL12 (also known as SDF-1),
which primarily signals via its specific receptor CXCR4 [1–3].
CXCR7 transcripts are widely and highly expressed in many
organs, including the brain [2,4–6]. However, discrepancy between
RNA levels and surface expression of CXCR7 has been noted in
various organs [2] suggesting that regulation of CXCR7 expression
is tightly regulated at the protein level and may be tissue-specific.
As with other chemokine receptors, CXCR7 belongs to the
superfamily of seven-transmembrane (7TM) G protein coupled
receptors, though current evidence indicates that CXCR7 does
not stimulate typical G protein-dependent pathways, and may act
as a b -arrestin-biased receptor [7–9] and/or as a chemokine
scavenger, particularly during development or in the tumor
microenvironment – i.e. sequestration of CXCL12 by binding to
CXCR7 may help create a CXCL12 gradient in the extracellular
space, resulting in proper chemotaxis/migration of CXCR4-
expressing cells [8,10,11]. Other studies suggest that CXCR7 may
form heterodimers with CXCR4 [9,12–15], thus serving as a
modulator of CXCR4 signaling, but the functional outcome and
mechanistic insights are still controversial. Enhanced responses to
CXCL12 (i.e. calcium flux and mitogen-activated protein kinase
activation) were observed in CXCR4 positive cells expressing
recombinant CXCR7 as compared to cells that express only the
endogenous CXCR4 protein [13]. On the other hand, variable
results have been reported regarding the potential role of
CXCR7 in modulating CXCL12-induced chemotaxis [14]
though some controversy still exists about the endogenous expre-
ssion of CXCR7 in lymphocytes. Also, CXCR7 can interfere with
CXCR4-dependent rapid integrin activation [15] and transen-
dothelial migration [12]. Overall, these results suggest that
CXCR7 can modulate CXCL12/CXCR4 signaling in non-
neuronal cells via multiple mechanisms.
The CXCL12/CXCR4 axis is essential to proper brain
development and is involved in homeostasis of the mature brain,
as it regulates fundamental neuronal and glial functions (i.e. cell
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20680survival, differentiation, migration, and synaptic activity) [16–18].
Furthermore, this chemokine/receptor pair is implicated in
various neuropathologies and neuroinflammatory conditions,
including brain tumors and neuroAIDS [16,19–22]. Interestingly,
CXCR7 may also support HIV-1 infection in glioma cells under
specific circumstances [23]. Hence, it is important to examine
CXCR7 protein expression and function in normal and disease
states in order to determine its ability to regulate CXCL12-
stimulated signaling in the brain and influence neuropathology.
To this end, we studied the expression of CXCR7 in cultured
neurons and in the brains of HIV-1 positive and negative subjects.
Our data provide the first evidence of CXCR7 protein expression
in normal and diseased adult human neurons in situ and show that,
in differentiated cultured neurons, CXCR7 is predominantly
expressed in intracellular compartments, it is virtually absent from
the cell surface, and does not alter CXCR4-mediated survival
signaling through pERK/Akt. Interestingly, neuronal CXCR7
largely co-localizes with the intracellular pool of CXCR4,
suggesting that it may interact with CXCR4. Along with previous
evidence, these results underscore the role of the CXCL12/
CXCR4 axis in cortical neurons and indicate that CXCR7 protein
in these cells is tightly controlled both temporally and spatially,
and it could contribute to the intracellular fate of CXCR4.
Materials and Methods
Ethics statement
All experiments involving animals were performed according to
protocols approved by the Institutional Animal Care and Use
Committee (Protocol Number: 18547) at Drexel University
College of Medicine. This study used archived human brain tissue
samples from HIV patients and control individuals. The samples
have been provided by brain banks participating to the National
NeuroAIDS Consortium and included specimens from unidenti-
fied patients of both sexes and different races. The Institutional
Review Board of Drexel University has reviewed our protocol and
approved it as Exempt Research (#18452).
Reagents
The anti-CXCR7 (clone11G8) antibody, which recognizes the
first 20 residues of the N-terminus of CXCR7, and the high-affinity
CXCR7 ligands were a gift from ChemoCentryx [2,12,24,25] and
used as reported below. The small-molecule compounds tested in
the present study include: CCX733, CCX754, CCX771, and
CCX704(an‘‘inactive’’analogueofCCX771).Thepolyclonal anti-
CXCR7 antibody, ab72100, was purchased from Abcam (Cam-
bridge, MA). Unless otherwise specified, reagents and media for the
cell culture were purchased from Invitrogen/Gibco (Carlsbad, CA)
or Sigma-Aldrich (St. Louis, MO).
Immunohistochemistry and source of human tissue
Immunohistochemistry analysis of human brain tissue was
conducted as we previously described [26]. A Breast Cancer
Tissue Array (BR721, US Biomax, Rockville, MD) containing
normal and 24 cancer samples was used to confirm CXCR7
antibody specificity in our hands, based on previous reports [2,27].
A human organ tissue array containing 33 types of normal organs
was purchased from US Biomax (FDA996t). A total of nine brain
autopsy samples from two groups of patients (Table 1) were
obtained from the tissue banks of the National NeuroAIDS Tissue
Consortium (NNTC) [28]. Specimens included samples from the
cerebral cortex and hippocampus of patients with HIV infection or
control patients (HIV negative). After deparaffinization and
quenching of endogenous horseradish peroxidase, sections were
incubated at 95uC in Target Retrieval Solution (Dako, Carpin-
teria, CA) for 1 h. Endogenous avidin/biotin was blocked in
blocking buffer (Vector Laboratories, Burlingame, CA). Sections
were incubated in Tris-buffered saline with 10% normal donkey
serum (Jackson ImmunoResearch, West Grove, PA), 2% milk, and
2% bovine serum albumin for an additional hour, and then
overnight with an anti-CXCR7 monoclonal (10 mg/mL, 11G8,
ChemoCentryx) or an anti-CXCR7 polyclonal antibody (10 mg/
mL, ab72100, Abcam). Comparison between these two antibodies
for CXCR7 showed similar results in adjacent sections, as shown
later; however, 11G8 was preferred in the present study, due to its
high specificity in both tissue preparations and isolated cells [24].
Biotin-conjugated donkey anti-mouse or a biotin-conjugated
donkey anti-rabbit antibody (1:500, Jackson ImmunoResearch)
was used to detect primary antibodies. Staining was visualized with
3,39-diaminobenzidine (Vector Laboratories). Serial sections of
tissue were stained with hematoxylin and eosin (H&E). Negative
controls (i.e., isotype control or no primary Ab) were included as
indicated. Sections were observed under a Nikon microscope
(OPTIPHOT-2) connected to a CCD camera (DP70, Olympus,
Melville, NY) or Zeiss Axio microscope connected to a CCD
camera (Nuance 2.10, CRi, Woburn, MA), and images were taken
using the DP (Olympus) or Nuance software, respectively. For
identification of CXCR7 positive neurons, sections were incubated
Table 1. Patient demographics, viral load, and CD4 counts.








Control 52 Male White 17.5 C/H N/A N/A N/A
Control 59 Female Black 10 C/H N/A N/A N/A
Control 59 Male White 18 C/H N/A N/A N/A
HIV 64 Male White 5.5 C/H 61 75 7484
HIV 44 Male Black 21.3 C/H 234 16,909 618
HIV 44 Male White 35 C/H 147 ,50 N/A
HIV 30 Male Black 6 C/H 8 104,300 14
HIV 43 Male Hispanic 31 C/H 3 110,493 65
HIV 43 Male Black 6 C/H 10 48,520 134
PMI: post-mortem interval, h: hour, C: cortex, H: hippocampus.
doi:10.1371/journal.pone.0020680.t001
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(a+b) (Millipore), followed by 30 minutes incubation with Alexa
647–conjugated goat anti-mouse and Alexa 546–conjugated goat
anti-rabbit antibodies (1:200, Invitrogen), respectively. Images
were captured with a Zeiss LSM5 Exciter laser scanning confocal
microscope (Thornwood, NY) using sequential imaging to prevent
interchannel cross-excitation between fluorochromes.
Cell Cultures
Human neurons were purchased from ScienCell Research
Laboratories (San Diego, CA), maintained in the neuronal culture
medium as indicated by the vendor, and used at 14–21 days in vitro
(DIV). Rat cortical neurons were obtained from rat embryos (E17)
and cultured in the absence of glia in serum-free defined media, as
we previously described [29,30]; cells were typically used for
experiments in their second week of culture (8–14 DIV), i.e. when
they are fully differentiated. MAP2 and GFAP staining were used to
identify neurons and astroglia, respectively. Human breast cancer
cells (MDA-MB-435) and human glioblastoma cells (U87MG,
U343MG) were cultured as previously described [2,15,31,32].
Immunocytochemistry
Cells on coverslips were labeled with the Image-iT LIVE Plasma
Membrane and Nuclear Labeling kit from Invitrogen/Molecular
Probes and then fixed in 4% paraformaldehyde. Cells were then
permeabilized with 0.1% Triton X-100 for 5 minutes. The
following antibodies were used: mouse anti-CXCR7 (50 mg/mL,
ChemoCentryx; 11G8), mouse anti-CXCR4 (1:200, R&D Systems,
Minneapolis, MN; 12G5), rabbit anti-MAP2 (a+b) (1:200; Milli-
pore, Billerica, MA), rabbit anti-GFAP (1:200; Santa Cruz
biotechnology, Santa Cruz, CA), rabbit anti-EEA1 (1:200; Cell
Signaling), rabbit anti-Rab7 (1:50; Cell Signaling), rabbit anti-
Rab11 (1:100; Cell Signaling), and rabbit anti-ERp29 (1:500; Cell
Signaling). Double staining was performed sequentially with
CXCR7 (Alexa 488–conjugated donkey anti-mouse as a secondary
antibody) always preceding the other primary antibodies, followed
by biotin-conjugated antibodies (either anti-mouse or anti-rabbit) as
secondary antibodies, and visualized by streptavidin conjugated to
Alexa Fluor 647. Confocal imageswere captured with eithera Leica
TCSSP2(Bannockburn,IL)ora ZeissLSM5Exciterlaserscanning
confocal microscope (Thornwood, NY) using sequential imaging to
prevent interchannel cross-excitation between fluorochromes.
Images were captured every 0.4–0.5 mm for z-scan.
RT-PCR
Total RNA was extracted using the RNeasy mini kit (Qiagen,
Valencia, CA). RNA obtained from rat and human cell lines was
treated with DNase prior to RT reaction. cDNA was synthesized
from total RNA. The following primers were used for amplifica-
tion: rat CXCR7: 59-GTGCAGCATAACCAGTGGCC-‘ and 59-
AGCAAAACCCAAGATGACGGA-39 [33], human CXCR7: 59-
AGCACAGCCAGGAAGGCGAG-39 and 59-TCATAGCCTG-
TGGTCTTGGC-39, human 28S: 59-GTTCACCCACTAATA-
GGGAACGTGA-39 and 59-GGATTCTGACTTAGA GGCGT-
TCAGT-39, human 59- GAPDH: CATTGACCTCAACTACAT-
GG-39 and 59-GGGCCA TCCACAGTCTTCTG-39, rat aldolase
A: 59-AACCAATGGCGAGACCACTAC-39 and 59-AATTTCA-
GGCTCCACAATGG-39. PCR was performed as follows: 4
minutes at 95uC, followed by 35 cycles of 30 s at 95uC, 30 s at
61uC, and 60 s at 72uC. For gel electrophoresis analysis, each
amplicon was generated and visualized using ethidium bromide
staining after electrophoresis on a 2% agarose gel. Aldolase A (rat),
28S (human) and GAPDH (human) were used as loading controls.
Western Blot
Cells were washed with ice-cold balanced salt solution and
scraped in lysis buffer (50 mM Tris, 150 mM NaCl, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 10 mM
Na4P2O7, 5 mM ethylenediaminetetra-acetic acid [EDTA], 1%
Triton X-100, 1 mM dithiothreitol, protease and phosphatase
inhibitor cocktails) as reported previously [34–36]. Equal amounts
of proteins as determined by the bicinchoninic acid assay from
Thermo Scientific (Rockford, IL) were loaded in each lane,
separated by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE), and transferred to polyvinylidene fluoride
membranes for immunoblotting. The following primary antibodies
were used for ERK/Akt studies as previously reported [30]: anti-
pERK1/2 (1:1000, cat#9101, Cell Signaling, Danvers, MA), anti-
ERK1/2 (1:1000, cat#9102, Cell Signaling), anti-pAkt (1:1000,
cat#9271, Cell Signaling), anti-Akt (1:1000, cat#9272 Cell
Signaling). Anti-actin was used for loading control (1:5000,
cat#A2066, Sigma-Aldrich). Different monoclonal and polyclonal
antibodies against CXCR7 were tested, often with inconclusive
results (not shown). The polyclonal antibody from Abcam ab72100
(1:500) is shown here; however, since this antibody can pro-
duce non specific bands in non-neuronal cells [24], additional
experimental approaches were used to confirm expression of
CXCR7 in rat neurons, as described in the results. Bands were
detected by chemiluminescence using SuperSignal West Femto
(Thermo Scientific), and analyzed using the FluorChem 8900
apparatus from Alpha Innotech (San Leandro, CA). Cell surface
protein separation was performed as we previously reported [30]
using a thiol-cleavable amine-reactive biotinylation reagent
(Thermo Scientific). After isolation of biotin-labeled cells, SDS-
PAGE and Western blotting were performed.
Binding Assay
Cells (2610
5 per well) were diluted in HBSS containing 0.1%
BSA and transferred to 96-well plates (100 ml per well) containing
5 ml per well recombinant CXCL11 or CXCL12 (final concen-
tration 100 nM) or compounds CCX771, CCX704 or AMD3100
(final concentration 1 mM). One hundred ml per well of cold buffer
containing 0.025 mCi (1 nM) 125I-CXCL12 (PerkinElmer) was
added and the plates were shaken at 4uC for 3 h. Cells were
transferred onto polyethyleneimine-treated GF/B glass fiber filters
(PerkinElmer) with a cell harvester (Tomtech) and washed with
25 mM HEPES, 500 mM NaCl, 1 mM CaCl2, 5 mM MgCl2,
pH 7.1. Fifty ml per well of MicroScint-20 (PerkinElmer) was
added to the filters and cpm were measured on a Packard Top-
Count scintillation counter (PerkinElmer). Assays were performed
in triplicate.
Statistical Analysis
One-way analysis of variance, followed by the Newman-Keuls
multiple comparison procedure, was used for statistical analysis.
All data are reported as the mean 6 SEM (n=3 for Western blots
and n=4 for radioligand binding assays).
Results
CXCR7 Expression in Adult Human Neurons: analysis of
normal and HIV-positive brains
Previous studies have demonstrated that CXCR7 protein is
specifically expressed in human breast cancer as opposed to
normal breast tissue [27]. Therefore, our first step consisted in
testing our staining protocol with the 11G8 antibody using a
human tissue microarray that contained normal breast tissue
and multiple breast carcinomas on the same slide. As expected,
CXCR7 Protein Expression in Neurons
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normal breast tissue. Two examples are reported in Figure 1 (A/
D). This figure also shows the typical alterations of the glandular
structure in the cancer tissue as compared to normal (counter-
staining in 1B/E), higher magnification images of selected areas
(square insets), and a negative control (1C).
Next, a tissue microarray containing samples of various normal
human organs, including the brain, was analyzed. Initial studies
with 11G8 showed a typical neuronal staining in the cerebral gray
matter (Figure 2A/E); CXCR7 staining was also seen in tubular
formation in the kidney (Figure 2C), in line with a previous
study [37], while normal breast tissue was negative as expected
(Figure 2B). Staining in the gray matter was also confirmed
by using another CXCR7 antibody (ab72100, Figure 2D) that
recognizes distinct portions of the receptor, i.e. epitopes in the
second extracellular loop as opposed to the N-terminus recognized
by 11G8. Though both these antibodies indicated neuronal
expression of CXCR7, we primarily used 11G8 to keep con-
sistency with the rest of the data.
Following this initial validation, we started the analysis of the
human tissue samples from the NNTC to determine expression of
CXCR7 RNA (Figure 3A) and protein (Figure 3B–F) in both
control and HIV patients. Brain samples (frontal cortex and
hippocampus) from control subjects and HIV+ patients included a
total of 9 subjects of different race, age, and gender as indicated in
Table 1. The data in normal brain tissue confirmed our previous
observations with the tissue arrays. As shown in Figure 3, both
CXCR7 RNA and protein are found in the human brain.
CXCR7-expressing cells were identified as neurons based on
morphology/localization (Figure 3B) as well as co-staining with the
neuronal marker MAP2 (Figure 3D). CXCR7-positive cells were
observed in both cortex (Figure 3A–D) and hippocampus
(Figure 3E/F) of control and HIV patients. Our analysis primarily
focused on MAP2 positive cells in the frontal cortex, since the
major goal of this study was to evaluate expression of the CXCR7
protein in mature cortical neurons. These IHC studies showed
that the vast majority of MAP2 positive cells are also positive to
CXCR7. Specifically, within the population of cells that stained
positively for MAP2, the percentage of cells also expressing
CXCR7 was 95% and 91%, respectively, in control and HIV
tissue (total number of cells analyzed=125 cells; these included
CXCR7+/MAP2+, CXCR7+/MAP2-, and CXCR7-/MAP2+).
These data suggest that both excitatory and inhibitory mature
neurons express the CXCR7 protein and are in agreement with
recent studies in the developing brain showing expression of cxcr7
transcripts in migrating interneurons as well as immature
excitatory neurons [38]. Furthermore, in these human brain
samples only a minority of CXCR7 positive cells (i.e. 11% and
11.4% respectively control/HIV) did not stain for MAP2. As
MAP2 is a marker for mature neurons, this smaller group of cells
could include resident/infiltrating immune cells (including glia)
and/or neural precursors. Further studies are necessary to fully
Figure 1. Staining of breast carcinoma with the CXCR7 antibody 11G8. A tissue array, containing samples from infiltrating ductal carcinoma
and normal breast tissue, was stained to examine CXCR7 expression using the monoclonal antibody 11G8 (10 mg/mL)-as described in the methods.
Representative images from infiltrating ductal carcinoma or normal tissue are shown here. Adjacent sections of the same samples were stained with
Hematoxylin and Eosin (H&E) or the isotype (i.e. mouse IgG1) control, as indicated for each panel. (A/B/C) Infiltrating ductal carcinoma (NC=isotype
control). (D/E) Normal breast tissue. (A2, B2, E2) High magnification of black squares in A, B, and E, respectively. Scale bars: 400 mm (A–E), 100 mm (A2,
B2, E2).
doi:10.1371/journal.pone.0020680.g001
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(i.e. to establish cell types, differentiation stages, and leukocytes
infiltration) and its potential changes during disease progression in
specific brain areas. Analysis of a larger group of samples is
underway to achieve this goal and to identify potential differences
in the expression of CXCR7 between HIV-positive patients
without neurological problems and HIV positive patients affected
by neurocognitive impairment. The present study demonstrates
that CXCR7 protein is widely expressed in mature neurons of the
human frontal cortex and hippocampus under both normal and
diseased (i.e. HIV) conditions, thus providing the fundamental
basis of future investigations focused on its specific role in brain
pathology.
CXCR7 Expression in Cultured Neurons and its relation to
CXCR4
To gain greater insights about the cellular localization of
CXCR7 in neurons, we studied expression of CXCR7 in human
brain cultures by immunocytochemistry and confocal microscopy.
Most neurons (identified by positive staining for the neuronal
marker, MAP2) expressed CXCR7, mainly in perinuclear regions
(Figure 4). All CXCR7-positive cells also expressed CXCR4
(Figure 4 and 5A), indicating that CXCR7 and CXCR4 were
present in the same populations of neurons. However, CXCR7
was predominantly expressed in the cytoplasm, whereas CXCR4
was also found on the cell membrane. Interestingly, most CXCR7
staining overlaps with CXCR4’s cytosolic staining (yellow area in
Figure 5B), suggesting that the two receptors may interact at the
intracellular level. The phenotype of intracellular retention of
CXCR7 did not seem to be limited to neurons but also observed in
some non-neuronal human cell lines (i.e. U87MG), as shown in
Figure S1. This figure reports studies with different CXCR7
positive (U87MG or U343) and negative (MDA-MB-435) cells.
Though CXCR7 transcripts are expressed in both U87MG and
U343 cells (Figure S1A) as expected, flow cytometry and
radioligand binding assays show CXCR7 protein expression only
on the surface of U343 (Figure S1B). Furthermore, CXCR7 was
detected in the cytoplasm of U87MG cells by confocal microscopy,
but not on the cell surface (Figure S1B). Next, we asked whether
this unique pattern of CXCR7 expression is human specific. To
this end, we first confirmed the expression of CXCR7 mRNA in
cultures of rat cortical neurons as well as in the rat cortex
Figure 2. CXCR7 protein expression in the human brain. Staining with 11G8 or ab72100 was performed on different human tissues, using
either a tissue array containing samples from multiple normal organs or additional brain sections as described in the methods. Images from the multi-
organ array are shown in the top panels (A to C; scale bars: 200 mm). Neuronal CXCR7 expression was observed in the gray matter (A) while no
staining is observed in normal breast tissue (B), as expected. CXCR7 was also expressed in the kidney (C). Additionally, serial sections from human
frontal cortex were stained with: (D) rabbit polyclonal antibody ab72100, (E) 11G8, or (F) H&E (details in methods). Similar neuronal staining was
observed with both CXCR7 antibodies. No staining was detected when the primary antibody was omitted (G) or replaced by the isotype control (H).
Images in insets are higher magnification of D, E, and F. Scale bars: 400 mm (D–H), 50 mm for insets. NC=negative control.
doi:10.1371/journal.pone.0020680.g002
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protein in rat neurons using different approaches. Western blot
analysis showed no expression of CXCR7 in the surface protein
fraction as opposed to the total protein expression (Figure 6B).
Surface expression of CXCR4, which is known to internalize after
CXCL12 treatment [30], was also probed using the same
membrane as an internal control of protein extraction and
separation. Immunostaining and confocal microscopy on rat
primary neurons also confirmed the lack of CXCR7 protein
expression on the neuronal surface (Figure 6C). CXCR7 staining
(green) was detected predominantly in the intracellular region
and did not co-localize with the membrane marker (red). To
further support these results, surface expression of CXCR7 in
cultured neurons was assessed by competitive binding studies. In
agreement with the Western blot and confocal analysis,
radioligand binding failed to demonstrate CXCR7 at the cell
surface (Figure 6D/E). Rat neurons cultured for varying periods
of time (i.e. up to 14 DIV) were incubated with radiolabeled
Figure 3. CXCR7 mRNA/protein expression in the brain of normal subjects and HIV patients. (A) CXCR7 mRNA expression in the frontal
cortex of control subjects; human glioblastoma cells (U87MG) were used as a positive control; M=molecular markers; RT=reverse transcriptase. (B)
CXCR7 protein expression in cortex of control patients. (C) No staining was detected in adjacent slices when the primary Ab was replaced by the
isotype control. Scale bar is 0.2 mm in panels B through C and 50 mm in the lower left inset of panel B. (D) Double-staining with MAP2 (green) and
CXCR7 (red) in human cortex. Scale bar: 50 mm. NC: negative control (shown here is a staining using CXCR7 isotype control, no MAP2 primary, and
addition of all secondaries). (E/F) CXCR7 immunostaining was examined in the hippocampus from control subjects (E) and HIV patients (F). Expression
of CXCR7 protein seems predominant in cytoplasm in both groups. Scale bars: 10 mm.
doi:10.1371/journal.pone.0020680.g003
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20680Figure 4. CXCR7 protein expression in human cultured neurons. Human neurons cultured for up to 3 weeks were labeled with a plasma
membrane and a nuclear marker prior to fixation as described in the methods, using the Image-iT LIVE Plasma Membrane and Nuclear Labeling Kit.
After permeabilization, neurons were stained for chemokine receptors and neuronal marker (MAP2). In neurons, CXCR7 (11G8, green) appears to be
localized predominantly to the soma (A), mostly in the perinuclear region (B). A negative control without primary antibodies is shown in lower right
panel. Nuclei of surrounding (mostly dead) cells, often found in these primary human cultures, appear in intense blue (i.e. Hoechst staining);
membrane staining is shown in white in the bottom row of B. Scale bars: 20 mm.
doi:10.1371/journal.pone.0020680.g004
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transfected with CXCR7, i.e. 435R7), minimal binding of
125I-
CXCL12 is observed in rat neurons (independently of the age in
vitro, data not shown), confirming the lack of surface CXCR7.
Collectively, these results indicate that surface expression of
CXCR7 is negligible in cultured rat/human neurons while a
substantial pool of the receptor is found in the intracellular
compartment.
Figure 5. CXCR7 and CXCR4 protein expression in human cultured neurons. Human neurons were labeled with a plasma membrane and a
nuclear marker prior to fixation as described previously. After permeabilization, neurons were stained for chemokine receptors and neuronal marker
(MAP2). Unlike CXCR7, CXCR4 expression (12G5) in neurons was distributed to both the soma and processes (A) though the intracellular expression of
the two receptors overlapped in some areas of the neuronal cell body (B). Negative control (NC, Mouse IgG1 isotype) is shown in lower right panel.
Scale bars: 20 mm.
doi:10.1371/journal.pone.0020680.g005
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e20680Figure 6. CXCR7 mRNA and protein expression in rat neurons. (A) CXCR7 mRNA was detected in rat primary neurons as well as rat cerebral
cortex (Ctx, E17) by RT-PCR as a 354-bp band [33]. (B) Cell surface proteins were purified from 75 mg of control (CTRL) or CXCL12-treated total proteins
obtained from pure neuronal cultures. Forty micrograms of total proteins were loaded in the last two lanes. Molecular markers (M) were loaded in the
first lane. The same membrane was reprobed with anti-CXCR4. As expected, CXCR4 is expressed on the surface of neurons in control (CTRL), but
surface expression is reduced following internalization caused by CXCL12 treatment (1 hr, 20 nM). (C) The subcellular localization of CXCR7 in rat
neurons was also examined by confocal microscopy. A membrane (red, C2) and nuclear marker (blue, C3) were applied on live cells prior to
permeabilization. Neurons were then stained with anti-CXCR7 mAb (green, C4) and imaged using the Leica TCS SP2 confocal system (Plan
Apochromat 636oil immersion objective, scale bar: 20 mm). All figures are 0.5-mm z-scan images. CXCR7 was observed in the cytoplasm, but not on
the cell surface, in these primary neurons. (D–E) Binding assays using radiolabeled CXCL12 were used to determine membrane expression of CXCR7 in
primary neurons (D). MDA-MB-435 cells transfected with CXCR7 (here labeled as 453R7) were used as positive controls (E). Data represent the
mean6SEM. TB, total bound. *p,0.05 vs. TB and vs. AMD3100;ˆp,0.05 vs. TB and vs. CCX704.
doi:10.1371/journal.pone.0020680.g006
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ERK1/2 and Akt activation
The above results suggest limited to null expression of CXCR7
on the neuronal surface. Thus, functional assays were performed
to validate these observations with a different approach as well as
to establish the potential contribution of even minimal CXCR7
expression to CXCR4 signaling. Rat neurons were exposed to
CXCR7-specific ligands (CCX733 or CCX754, 100 nM) known
to inhibit CXCL12 binding to CXCR7 [2,8,9,25]. The goal was to
determine whether treatment with the small-molecule compounds
would affect the activation of intracellular pathways stimulated by
CXCL12, specifically phosphorylation of ERK1/2 and Akt. As we
previously demonstrated, activation of these pathways in neurons
depends on CXCR4, involves Gi/o proteins, and ultimately
promotes neuronal survival [30,35,39]. The results presented here
show that CCX733 or CCX754, applied to pure neuronal cultures
15 minutes before and during CXCL12 treatment (20 nM, for
indicated time), did not significantly alter CXCL12-induced
stimulation of ERK1/2 and Akt (Figure 7). The effect of
100 nM CCX733/754 is reported here, but similar results were
obtained in additional experiments using a wider range of CCX
concentrations, i.e. from 10 nM to 1 mM (not shown). Also, the
CXCR7 ligands did not induce ERK or Akt phosphorylation (nor
Gi stimulation, not shown) in the absence of CXCL12 (not shown).
These results are consistent with the lack of CXCR7 expression on
the neuronal surface and with previous reports with similar
compounds [21].
CXCR7 Protein Partially Co-localizes with The
Endoplasmic Reticulum Marker ERp29 in Human Neurons
The data presented show that CXCR7 is expressed in intra-
cellular compartments in differentiated neurons, but the exact
localization is still unclear. Previous studies in human T lym-
phocytes reported expression of CXCR7 in endosome vesicles,
though this finding is still controversial [15]. However, CXCR7
does not co-localize with early (EEA1) or late (Rab7, Rab11)
endosome markers in human neurons (Figure S2), suggesting that
CXCR7 plays different roles in neurons and immune cells. Further
analysis in neurons revealed a partial co-localization of CXCR7
with the endoplasmic reticulum (ER) marker ERp29 (Figure 8)
[40]. The ER is part of the secretory pathway implicated in
protein translocation to the cell surface, and it is commonly
considered a default pathway. These data suggest that CXCR7
may be re-directed to the cell surface under specific cellular
conditions or be implicated in trafficking of other proteins. Based
on the CXCR7/CXCR4 expression pattern shown previously
(Figures 4–5), this may include CXCR4-a hypothesis currently
under investigation in our laboratory.
Discussion
The 7TM receptor CXCR7 has received considerable attention
in the last few years, following the discovery of binding to
chemokines that are implicated in essential biological functions,
such as the chemokine CXCL12 [1,2]. Initial studies reported
expression of CXCR7 transcripts in various organ systems-
including the central nervous system [2,4]-but the actual level of
CXCR7 protein, its signaling capability, and related function in
different cell types are still not clearly defined. As demonstrated by
pioneering studies in rodents lacking CXCL12 or CXCR4 [41], as
well as by other evidence in vitro and in vivo, CXCR4 is the specific
and primary CXCL12 receptor. However, one major question
concerns the role of CXCR7 in modulating the effect of the
CXCL12/CXCR4 axis in the brain and other organs. Though
several hypotheses have been proposed (e.g. the scavenger or
decoy activity of CXCR7; a CXCR4/CXCR7 signaling cross-talk
or physical interactions between the two receptors that may affect
signaling) data about the expression of the CXCR7 protein in
individual brain cells are still scarce and inconclusive. Further-
more, the limited availability of research reagents that effectively
work in multiple animal species has hindered progress in this field
[24]. Only very recently studies that primarily looked at expression
of cxcr7 transcripts in migrating neurons using different transgenic
mouse lines have shed some light on CXCR7/CXCR4 interaction
in the developing brain [38,42].
Here we focused on the protein expression of CXCR7 in
human differentiated neurons as a foundation to further inves-
tigation on the role of CXCR7 in the neuroprotective action of
CXCL12. The results shown here, using different antibodies,
experimental approaches, and multiple controls indicate that
CXCR7 protein expression in mature neurons is mostly limited to
the intracellular compartment and seem to exclude a prominent
role of this receptor in the immediate regulation of typical
pathways triggered by neuronal CXCR4, such as the activation of
ERK1/2 and Akt [30]. This is suggested by the perinuclear
localization of the CXCR7 staining in human brain tissue and
cultured neurons and the inability of the high-affinity CXCR7
ligands to inhibit CXCL12 binding as well as CXCL12/CXCR4
functional assays in rat neurons. Interestingly, in migrating
interneurons CXCR7 can contribute to CXCL12 signaling by
regulating surface expression of CXCR4 and, in line with our
data, it is prevalently expressed at the intracellular level [38].
Another study [42] suggested that CXCR4 and CXCR7 have
distinct functions in the regulation of interneuron movement and
laminar positioning. Though both of these studies are in
agreement with our findings concerning localization of CXCR7
in differentiated neurons, the distinct roles of CXCR7 in mature
neurons and neural precursors (which also express CXCR7 [21])
remain to be established.
Furthermore, disconnect between expression of the CXCR7
message and its expression on the surface of cells is not totally
unexpected. While transcription of many 7TM receptors leads to a
rapid translation and transport of receptor to its signaling position
at the cell surface, some receptors appear to be retained in the cell
cytoplasm as a form of post-translation regulation. For instance the
chemokine receptor CXCR2 can be sequestered to the cytoplasm
of neutrophils, with its surface expression regulated by glycosyl-
ation, which serves to release the intracellular pool to the cell
membrane [43]. Similarly, N-linked glycosylation appears to play
a role in correct folding and trafficking to the plasma membrane of
the vasoactive intestinal peptide receptor 1 (VIPR1) and GABA-
transporter 1 receptors [44,45]. Thus, post-translational retention
of CXCR7 in the endoplasmic reticulum may play an important
role in the biology of the CXCR7 receptor, with post-translational
modifications or other external stimuli regulating localization and
function.
Moreover, the co-expression of CXCR4 and CXCR7 in specific
compartments suggests that CXCR7 may interact with CXCR4 at
the intracellular level; for instance, CXCR7 may control surface
levels of CXCR4 by limiting its intracellular trafficking (supported
by the presence of CXCR7 in the ER) or it can alter CXCR4
interaction with other signaling molecules as suggested in other
studies [14]. However, protein expression and localization of
CXCR7 seems to be specifically regulated in different cell types
and its function may significantly vary in neuronal versus non-
neuronal cells. This is suggested by studies in lymphocytes and
breast cancer cells showing CXCR7 protein expression in different
intracellular compartments [8,15], such as early/late endosomes
CXCR7 Protein Expression in Neurons
PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e20680Figure 7. CXCL12-induced phosphorylation of ERK or Akt in the presence of CXCR7 ligands. (A) Rat cortical neurons were treated with
the CXCR7 ligands CCX733 (100 nM) or CCX754 (100 nM) 15 minutes before (and during) their exposure to vehicle or CXCL12 (20 nM, as indicated).
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as the delta opioid receptor [46], the D1 receptor [47,48], and the
CCR5 chemokine receptor [49], have shown that these receptors
normally reside in the cytoplasm and translocate to the cell
membrane upon interaction with chaperones/escort proteins
triggered by specific stimuli (see review [50]). Other studies have
reported that in T lymphocytes the majority of CCR5 is found in
the ER and the Golgi apparatus [49] but is transported to the cell
surface after transfection of CD4, indicating that receptor surface
expression is regulated by specific factors [49]. TNF-a and IL-1b
can up-regulate chemokine receptors (including CXCR7) in
different cells [2,21]. However, we did not find this to be the
case in human/rat neurons, as CXCR7 expression is still
negligible on the surface of human neurons treated with TNF-a
or IL-1b (10 ng/mL, up to 72 hrs; data not shown). As alterations
of CXCL12/CXCR4 function are thought to contribute to
neuropathology, including neuroAIDS, we also asked whether
changes in CXCR7 expression between normal and HIV-positive
brain tissue could be involved in CXCR4 impairment. A first step
in this direction was to examine overall expression of the CXCR7
Figure 8. CXCR7 partially co-localizes with endoplasmic reticulum marker ERp29. Human neurons were incubated with antibodies against
CXCR7 (11G8, green) and ERp29 (red) as reported above and in the methods. Mouse IgG1 isotype control was used as negative control (NC).
Overlapping staining of CXCR7 and ERp29 (yellow) is detected in many neurons mostly in the perinuclear region. Image labeled as ‘‘Merged’’ is an
enlargement of the CXCR7+ERp29 image shown in the inset plus the nuclear staining, whereas the image labeled as ‘‘lower plane’’ is the merge of
CXCR7+ERp29 from a different plane of the same cell. Scale bar: 10 mm.
doi:10.1371/journal.pone.0020680.g008
Activation of survival pathways (i.e., ERK/Akt) induced by CXCL12 was measured by Western blot analysis using phosphospecific antibodies [30]. (B/C)
Densitometric analysis showed no significant difference in pERK (analysis of variance [ANOVA]; NS, part B) or pAkt (ANOVA; NS, part C) bands after
CCX733/754 treatment compared with CXCL12 alone. Total ERK and Akt were used for normalization of pERK and pAkt, respectively. Data represent
the mean6SEM, as obtained in three independent experiments.
doi:10.1371/journal.pone.0020680.g007
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subjects in order to gather preliminary information about
distribution of CXCR7 in the adult brain under physiological
and pathological conditions. Based on the information collected
from these studies, i.e. general distribution of CXCR7 in the two
group of subjects, control and HIV-positive, we have started a
larger and more detailed analysis of CXCR7 expression as it
relates to neurocognitive impairment by using multispectral
microscopy and laser capture microdissection. Though progress
of these studies is relatively slow, due to the complexity of the
technical approach and limited availability of the brain samples,
they will provide crucial information about the role of CXCR7 in
the regulation of CXCR4 in vivo.
In conclusion, our data provide the first evidence of CXCR7
protein expression in human differentiated neurons, both in vivo
and in culture, laying the foundation for subsequent studies to
characterize the physiological and pathological role of CXCR7 in
the adult brain. Collectively, the results so far exclude a substantial
role of CXCR7 in the short-term survival signaling stimulated by
CXCL12 in neurons. This is not only an important information
about the overall function of CXCL12 in the brain, but a potential
positive result supporting ongoing efforts toward development of
CXCR7-based therapies against cancer and other pathologies.
Based on these data, use of specific CXCR7 ligands that target
CXCR7-positive cells [12,27] is not expected to be associated with
direct neuronal damage or immediate impairment of neuronal
CXCR4 function. However, these studies also raise the possibility
that CXCR7/CXCR4 interactions in intracellular compartments
can control CXCR4 trafficking to the surface and regulate
CXCR4 coupling to other proteins. As recycling/degradation and
delayed intracellular signaling are essential components of 7TM
receptors’ physiopathology, this supportive action of CXCR7 may
have important consequences on CXCR4 long-term function. In
line with these conclusions, a recent report has shown that
CXCR7 can control CXCR4 levels in vivo via modulation of its
degradation [38]. Therefore, further characterization of this
interesting protein in specific brain cell populations under normal
and pathological conditions should lead to a better understanding
of the numerous CXCL12 functions in the CNS and should be
highly encouraged.
Supporting Information
Figure S1 Variable expression of CXCR7 protein on the
cell surface in different CXCR7-positive cells. CXCR7
mRNA was detected in U87MG and U343 cells, but not the MB-
MDA-435 or no template controls by RT-PCR. Despite abundant
CXCR7 message (A), cell surface CXCR7 could not be
demonstrated in U87MG cells by radioligand binding (B, top) or
FACS (B, bottom) in contrast to the U343 positive controls. Using
immunofluorescence, CXCR7 was localized to the cytoplasm of
U87MG cells (C1) as reported in neurons (C2/C3). Data represent
the mean6SEM. Scale bar: 20 mm.
(TIF)
Figure S2 CXCR7 does not colocalize with early to late
endosome markers. Human neurons were stained for CXCR7
and early (EEA1) or late (Rab7, Rab11) endosomal markers.
CXCR7 staining does not overlap with any of the markers used in
this study. Mouse IgG1 isotype control was used as negative
control (NC). Scale bars: 20 mm.
(TIF)
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